2018 UPDATE AND 2019 OUTLOOK GIVEN AT THE CPHI CONFERENCE:
- Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for US market
- Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions
- Further Marketing authorisations obtained for MyRing™
- Continuously improved IP portfolio
- Strenghtened cash position
Read the full press release here.
